Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya K Leabman

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Pharmacogenetics|September 16, 2003
Estimating the contribution of genes and environment to variation in renal drug clearanceMaya K Leabman, Kathleen M Giacomini
Journal of Pharmaceutical Sciences|November 25, 2005
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variantsTomoe Fujita, Thomas J Urban, Maya K Leabman, et al.
Mabs|February 5, 2014
Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeysMaya K Leabman, Y Gloria Meng, Robert F Kelley, et al.
Genome Research|December 16, 2005
Functional genomics of membrane transporters in human populationsThomas J Urban, Ronnie Sebro, Evan H Hurowitz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2009
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primatesYik Andy Yeung, Maya K Leabman, Jonathan S Marvin, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|February 27, 2003
SNP analysis and presentation in the Pharmacogenetics of Membrane Transporters ProjectDoug Stryke, Conrad C Huang, Michiko Kawamoto, et al.
Pharmacogenetics|July 27, 2002
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered functionMaya K Leabman, Conrad C Huang, Michiko Kawamoto, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 2003
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1Yan Shu, Maya K Leabman, Bo Feng, et al.
Pharmacogenetics and Genomics|June 2, 2009
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metforminYing Chen, Shuanglian Li, Chaline Brown, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 2003
Natural variation in human membrane transporter genes reveals evolutionary and functional constraintsMaya K Leabman, Conrad C Huang, Joseph DeYoung, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Pharmacogenetics|September 16, 2003
Estimating the contribution of genes and environment to variation in renal drug clearanceMaya K Leabman, Kathleen M Giacomini
Journal of Pharmaceutical Sciences|November 25, 2005
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variantsTomoe Fujita, Thomas J Urban, Maya K Leabman, et al.
Mabs|February 5, 2014
Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeysMaya K Leabman, Y Gloria Meng, Robert F Kelley, et al.
Genome Research|December 16, 2005
Functional genomics of membrane transporters in human populationsThomas J Urban, Ronnie Sebro, Evan H Hurowitz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2009
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primatesYik Andy Yeung, Maya K Leabman, Jonathan S Marvin, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|February 27, 2003
SNP analysis and presentation in the Pharmacogenetics of Membrane Transporters ProjectDoug Stryke, Conrad C Huang, Michiko Kawamoto, et al.
Pharmacogenetics|July 27, 2002
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered functionMaya K Leabman, Conrad C Huang, Michiko Kawamoto, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 2003
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1Yan Shu, Maya K Leabman, Bo Feng, et al.
Pharmacogenetics and Genomics|June 2, 2009
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metforminYing Chen, Shuanglian Li, Chaline Brown, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 2003
Natural variation in human membrane transporter genes reveals evolutionary and functional constraintsMaya K Leabman, Conrad C Huang, Joseph DeYoung, et al.
Pageof 2